Download PDF
Dtsch Med Wochenschr 2003; 128(8): 378-385
DOI: 10.1055/s-2003-37378
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Therapie chronisch entzündlicher Darmerkrankungen mit Azathioprin, 6-Mercaptopurin und 6-Thioguanin

Klinisch-pharmakologische Aspekte[1] Clinical pharmacology of azathioprine, 6-mercaptopurine and 6-thioguanine in the treatment of inflammatory bowel diseasesM. Schwab1 , K. Herrlinger2 , E. Schaeffeler1 , E. F. Stange2
  • 1Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie (Direktor: Prof. Dr. med. M. Eichelbaum), Stuttgart
  • 2Abteilung für Innere Medizin 1, Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie (Chefarzt: Prof. Dr. med. E.F. Stange), Robert-Bosch-Krankenhaus, Stuttgart
Further Information

Publication History

eingereicht: 24.9.2002

akzeptiert: 15.1.2003

Publication Date:
20 February 2003 (online)

Also available at
    Permissions and Reprints

Azathioprin, 6-Mercaptopurin (6-MP) bzw. 6-Thioguanin nehmen sowohl in der immunsuppressiven wie auch in der zytostatischen Therapie einen besonderen Stellenwert ein. Die Gesamtverordnungszahlen für Azathioprin für das Jahr 2000 lagen nach Angaben des Arzneiverordnungsreports bei 320 900 [42]. In der gastroenterologischen Arzneimitteltherapie in Deutschland wird Azathioprin bevorzugt, währenddessen z. B. in den USA auch 6-MP vergleichsweise häufig verordnet wird. Das Indikationsspektrum für Azathioprin in der Gastroenterologie umfasst neben der Autoimmunhepatitis und der primär sklerosierenden Cholangitis v. a. die Therapie chronisch entzündlicher Darmerkrankungen (CED). Die vorliegende Arbeit gibt einen Überblick zur klinischen Pharmakologie von Azathioprin bei der Behandlung des Morbus Crohn (MC) und der Colitis ulcerosa (CU), wobei Aspekte zur Arzneimittelsicherheit bzw. zur Wirksamkeit von Azathioprin besonders berücksichtigt werden.

1 Unterstützt durch die Robert Bosch-Stiftung, Stuttgart und das BMBF (FKZ 01 GG 9846)

Literatur

  • 1 Aithal G P, Mansfield J C. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.  Aliment Pharmacol Ther. 2001;  15 1101-1108
    Google Scholar
  • 2 Andersen J B, Szumlanski C, Weinshilboum R M, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.  Acta Paediatr. 1998;  87 108-111
    Google Scholar
  • 3 Ansari A, Hassan C, Duley J. et al . Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.  Aliment Pharmacol Ther. 2002;  16 1743-1750
    Google Scholar
  • 4 Bär U, Becker H, May B. et al . Azathioprine pharmacokinetics in animal experiment and in patients with chronic liver diseases.  Verh Dtsch Ges Inn Med. 1973;  79 943-946
    Google Scholar
  • 5 Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new).  Inflamm Bowel Dis. 2001;  7 190-191
    Google Scholar
  • 6 Bebb J R, Aithal G P, Logan R P. Immunosuppression, IBD, and risk of lymphoma.  Gut. 2002;  51 296
    Google Scholar
  • 7 Belaiche J, Desager J P, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.  Scand J Gastroenterol. 2001;  36 71-76
    Google Scholar
  • 8 Bouhnik Y, Lemann M, Mary J Y. et al . Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine.  Lancet. 1996;  347 215-219
    Google Scholar
  • 9 Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.  Aliment Pharmacol Ther. 2002;  16 389-398
    Google Scholar
  • 10 Colombel J F, Ferrari N, Debuysere H. et al . Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy.  Gastroenterology. 2000;  118 1025-1030
    Google Scholar
  • 11 Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J K, Lennard-Jones J E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.  Lancet. 1994;  343 1249-1252
    Google Scholar
  • 12 Connell W R, Kamm M A, Ritchie J K, Lennard-Jones J E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.  Gut. 1993;  34 1081-1085
    Google Scholar
  • 13 Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity.  Gut. 1996;  39 401-406
    Google Scholar
  • 14 Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.  Gut. 2001;  48 642-646
    Google Scholar
  • 15 Dewit O, Vanheuverzwyn R, Desager J P, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease.  Aliment Pharmacol Ther. 2002;  16 79-85
    Google Scholar
  • 16 Dubinsky M C, Lamothe S, Yang H Y. et al . Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.  Gastroenterology. 2000;  118 705-713
    Google Scholar
  • 17 Ekbom A, Helmick C, Zack M, Adami H O. Extracolonic malignancies in inflammatory bowel disease.  Cancer. 1991;  67 2015-2019
    Google Scholar
  • 18 Elion G B. The purine path to chemotherapy.  Science. 1989;  244 41-47
    Google Scholar
  • 19 Evans W E, Hon Y Y, Bomgaars L. et al . Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.  J Clin Oncol. 2001;  19 2293-2301
    Google Scholar
  • 20 Fellermann K, Steffen M, Stein J. et al . Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.  Aliment Pharmacol Ther. 2000;  14 171-176
    Google Scholar
  • 21 Fellermann K, Tanko Z, Herrlinger K R. et al . Response of refractory colitis to intravenous or oral tacrolimus.  Inflamm Bowel Dis. 2002;  8 317-324
    Google Scholar
  • 22 Fraser A G, Orchard T R, Jewell D P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.  Gut. 2002;  50 485-489
    Google Scholar
  • 23 Fraser A G, Orchard T R, Robinson E M, Jewell D P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.  Aliment Pharmacol Ther. 2002;  16 1225-1232
    Google Scholar
  • 24 Harms D O, Janka-Schaub G E. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.  Leukemia. 2000;  14 2234-2239
    Google Scholar
  • 25 Herrlinger K R, Kreisel W, Schwab M. et al . 6-thioguanine - efficacy and safety in chronic active Crohn’s disease.  Aliment Pharmacol Ther. 2003;  im Druck
    Google Scholar
  • 26 Hildner K, Marker-Hermann E, Schlaak J F. et al . Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells.  Ann N Y Acad Sci. 1998;  859 204-207
    Google Scholar
  • 27 Kaskas B A, Louis E, Hindorf U. et al . Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine.  Gut. 2003;  52 140-142
    Google Scholar
  • 28 Kroeplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate.  Eur J Clin Pharmacol. 1998;  54 265-271
    Google Scholar
  • 29 Lennard L, Lilleyman J S, Van Loon J, Weinshilboum R M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.  Lancet. 1990;  336 225-229
    Google Scholar
  • 30 Lennard L. The clinical pharmacology of 6-mercaptopurine.  Eur J Clin Pharmacol. 1992;  43 329-339
    Google Scholar
  • 31 Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions.  Ther Drug Monit. 1998;  20 527-531
    Google Scholar
  • 32 Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine.  Gut. 2002;  51 143-146
    Google Scholar
  • 33 Lewis J D, Schwartz J S, Lichtenstein G R. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma.  Gastroenterology. 2000;  118 1018-1024
    Google Scholar
  • 34 Lewis L D, Benin A, Szumlanski C L. et al . Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction.  Clin Pharmacol Ther. 1997;  62 464-475
    Google Scholar
  • 35 Lowry P W, Franklin C L, Weaver A L. et al . Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.  Gut. 2001;  49 656-664
    Google Scholar
  • 36 Lowry P W, Franklin C L, Weaver A L. et al . Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.  Gut. 2001;  49 665-670
    Google Scholar
  • 37 Lowry P W, Szumlanski C L, Weinshilboum R M, Sandborn W J. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.  Gastroenterology. 1999;  116 1505-1506
    Google Scholar
  • 38 Ludwig D, Stange E F. German Imurek Study Group . Efficacy of azathioprine in the treatment of chronic active Crohn’s disease: prospective one-year follow-up study.  Z Gastroenterol. 1999;  37 1085-1091
    Google Scholar
  • 39 McBride K L, Gilchrist G S, Smithson W A, Weinshilboum R M, Szumlanski C L. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency.  J Pediatr Hematol Oncol. 2000;  22 441-445
    Google Scholar
  • 40 McGovern D P, Travis S P, Duley J, Shobowale-Bakre el M, Dalton H R. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity.  Gastroenterology. 2002;  122 838-839
    Google Scholar
  • 41 McLeod H L, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics.  Pharmacogenomics. 2002;  3 89-98
    Google Scholar
  • 42 Nink K, Schröder H. Ergänzende statistische Übersicht. Berlin: Springer-Verlag In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2001 2001: 846-930
    Google Scholar
  • 43 Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.  Lancet. 1993;  342 1514-1516
    Google Scholar
  • 44 Pearson D C, May G R, Fick G H, Sutherland L R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.  Ann Intern Med. 1995;  123 132-142
    Google Scholar
  • 45 Persson P G, Karlen P, Bernell O. et al . Crohn’s disease and cancer: a population-based cohort study.  Gastroenterology. 1994;  107 1675-1679
    Google Scholar
  • 46 Poordad F, Vasiliausless E, Abreu M. et al . Nodular regenerative hyperplasia (NRH) of the liver associated with 6-thioguanine (6-TG) therapy in inflammatory bowel disease (IBD) (abstract #680).  Hepatology. 2002;  36 333A
    Google Scholar
  • 47 Present D H, Meltzer S J, Krumholz M P, Wolke A, Korelitz B I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.  Ann Intern Med. 1989;  111 641-649
    Google Scholar
  • 48 Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.  Eur J Gastroenterol Hepatol. 2001;  13 287-290
    Google Scholar
  • 49 Sandborn W J, Tremaine W J, Wolf D C. et al. North American Azathioprine Study Group . Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease.  Gastroenterology. 1999;  117 527-535
    Google Scholar
  • 50 Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease.  Cochrane Database Syst Rev. 2000;  2 CD000545
    Google Scholar
  • 51 Sandborn W J. Rational dosing of azathioprine and 6-mercaptopurine.  G ut. 2001;  48 591-592
    Google Scholar
  • 52 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease.  Clin Pharmacokinet. 2001;  40 723-751
    Google Scholar
  • 53 Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn’s disease using phenotyping only.  Gastroenterology. 2001;  121 498-499
    Google Scholar
  • 54 Schwab M, Schaeffeler E, Marx C. et al . Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.  Pharmacogenetics. 2002;  12 429-436
    Google Scholar
  • 55 Sebbag L, Boucher P, Davelu P. et al . Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients.  Transplantation. 2000;  69 1524-1527
    Google Scholar
  • 56 Shipkova M, Armstrong V W, Wieland E, Oellerich M. Differences in Nucleotide Hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods.  Clin Chem. 2003;  49 im Druck
    Google Scholar
  • 57 Stange E F, Modigliani R, Pena A S, Wood A J, Feutren G, Smith P R. The European Study Group . European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study.  Gastroenterology. 1995;  109 774-782
    Google Scholar
  • 58 Stange E F, Riemann J, von Herbay A. et al . Diagnosis and therapy of ulcerative colitis-results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases.  Z Gastroenterol. 2001;  39 19-20
    Google Scholar
  • 59 Stange E F, Schreiber S, Foelsch U. et al . Diagnostik und Therapie des Morbus Crohn - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten.  Z Gastroenterol. 2003;  41 19-20
    Google Scholar
  • 60 Stolk L C, Broxson E H, Sather H. et al . Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia (abstract T833).  Gastroenterology. 2002;  122 (Suppl)
    Google Scholar
  • 61 Swann P F, Waters T R, Moulton D C. et al . Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.  Science. 1996;  273 1109-1111
    Google Scholar
  • 62 Szumlanski C L, Weinshilboum R M. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.  Br J Clin Pharmacol. 1995;  39 456-459
    Google Scholar
  • 63 Tidd D M, Paterson A R. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine.  Cancer Res. 1974;  34 733-737
    Google Scholar
  • 64 Tiede I, Fritz G, Wirtz S. et al . 6-Thio-GTP vermittelte funktionelle Hemmung der GTPase Rac1: Identifikation eines molekularen Wirkungsmechanismus von Azathioprin bei chronisch entzündlichen Darmerkrankungen (Abstrakt PL 6).  Z Gastroenterol. 2002;  40 603
    Google Scholar
  • 65 Van Os E C, Zins B J, Sandborn W J. et al . Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.  Gut. 1996;  39 63-68
    Google Scholar
  • 66 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.  Am J Hum Genet. 1980;  32 651-662
    Google Scholar
  • 67 Wood T C, Johnson K L, Naylor S, Weinshilboum R M. Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia.  Drug Metab Dispos. 2002;  30 1123-1128
    Google Scholar
  • 68 Yates C R, Krynetski E Y, Loennechen T. et al . Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.  Ann Intern Med. 1997;  126 608-614
    Google Scholar
  • 69 Zimm S, Collins J M, O’Neill D, Chabner B A, Poplack D G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.  Clin Pharmacol Ther. 1983;  34 810-817
    Google Scholar

1 Unterstützt durch die Robert Bosch-Stiftung, Stuttgart und das BMBF (FKZ 01 GG 9846)

Prof. Dr. E. F. Stange

Abteilung für Innere Medizin 1, Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie, Robert-Bosch-Krankenhaus

Postfach 50 11 20

70341 Stuttgart

Phone: +49/711/81013406

Fax: +49/711/81013793

Email: eduard.stange@rbk.de

      >